Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
5
×
drugs
5
×
life sciences
national blog main
alnylam pharmaceuticals
boston top stories
rna interference
boston
new york blog main
new york top stories
patisiran
akcea therapeutics
aminolevulinic acid
biotech
fda
givosiran
inotersen
national top stories
new york
onpattro
regeneron pharmaceuticals
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
anylam pharmaceuticals
barry greene
boston university
cardiomyopathy
dan ollendorf
evercore isi
evolocumab
heart attack
hereditary transthyretin amyloidosis
What
alnylam
5
×
drug
rna
ago
fda
medicine
pharmaceuticals
data
interference
medicines
new
patients
rnai
second
seek
speedy
akcea
amyloidosis
approval
approve
approved
attr
available
awaits
based
battle
biological
cholesterol
cleared
crossed
debilitating
decades
decision
discovered
disease
evidence
far
fingers
friday
genetic
Language
Current search:
drugs
×
alnylam
×
" clinical trials "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision